An important feature of bronchial asthma is airway hyperresponsiveness, with a predominance of eosinophils and mast cells, and is an airway allergic disease. Acute exacerbations can be life-threatening if poorly controlled. The clinical treatment of acute bronchial asthma exacerbations requires that the treatment be effective, fast and efficient, and that the patient’s inspiratory status be improved as soon as possible. The most commonly used theophylline drug is aminophylline, and with the popularity of the new drug doxorubicin, it has been found that doxorubicin is more effective in clinical practice, but what is good about doxorubicin? Huang Huaihuan et al. randomly divided 60 cases of elderly bronchial asthma patients into doxorophylline group and aminophylline group. 30 cases in each group were treated with doxorophylline in the doxorophylline group and aminophylline in the aminophylline group for 7 d. The efficiency, effectiveness and effectiveness of treatment in both groups were observed.
The treatment efficiency, changes in the indexes related to pulmonary ventilation function and adverse reactions were observed in the two groups. Results
The total effective rate of the doxorophylline group was 93.33%, which was significantly higher than that of the aminophylline group, and the difference was statistically significant (P=0.012); the improvement of cough, wheezing, disappearance of croup and wet rales in the doxorophylline group was significantly shorter than that of the aminophylline group, and the difference was statistically significant (P<0.05); after the treatment of the doxorophylline group, the indexes related to pulmonary ventilation function, the first second expiratory volume ( FEV1, FEV1 as a percentage of the expected value (FEV1/FVC), peak expiratory flow rate (PEFam) measured in the morning and peak expiratory flow rate (PEFpm) measured in the evening were significantly higher than those in the aminophylline group, and the difference was statistically significant (P<0.05); the incidence of adverse reactions in the doxorubicin group was significantly lower than that in the aminophylline group, and the difference was statistically significant (P=0.05). The difference was statistically significant (P=0.017). Dai Wei enrolled 74 patients with bronchial asthma as study subjects, and took the random number table method to divide into study group and control group, 37 cases in each group, the control group was treated with aminophylline, and the study group was treated with doxorubicin, both treated for 7d, to compare the clinical efficacy of the two groups. After treatment, the patients in the study group had better lung function improvement than the control group, and the treatment rate of the study group was 86.5%, which was higher than that of the control group (70.3%), and the difference between the two groups was statistically significant (P < 0.05); the improvement time of cough, kick and breath, disappearance time of rales and wet rales in the study group was significantly shorter than that of the control group, and the difference was statistically significant (P <0.05); the incidence of adverse reactions in the study group was lower than that in the control group, and the difference was statistically significant (P <0.05). In the study, 96 patients with bronchial asthma were randomly divided into two groups, the treatment group was given doxorubicin and the control group was given aminophylline, and the treatment effects, changes in lung function indexes before and after treatment and the incidence of adverse reactions in the two groups were analyzed. After treatment, the effect of the treatment group was better and the incidence of adverse reactions was lower compared with the control group, P < 0.05; while there was no significant change in the lung function indexes of the two groups before treatment, after treatment, the change in lung function of the treatment group was better compared with the control group, P < 0.05. Zhao Fen et al. took 62 patients with bronchial asthma as the study subjects and divided them equally into the control group and the observation group. The patients in the control group were treated with aminophylline and the patients in the observation group were treated with doxorubicin on the basis of conventional treatment. The treatment effect of bronchial asthma patients in the two groups was analyzed. The clinical treatment efficiency of the control group was 78.5%, and that of the observation group was 94.9%, with a statistically significant difference (P<0.05).
The clinical data of 60 patients with bronchial asthma were divided into aminophylline group and doxorubicin group according to the different treatment drugs (n=30) by Yu Feng et al.
The clinical efficiency, incidence of adverse reactions and changes of pulmonary function indexes at 36 h after treatment were observed. The results showed that the FEV1/FVC of patients in the doxorophylline group improved significantly compared with those in the aminophylline group, and the difference was statistically significant (P=0.000); the total clinical efficiency at 12 h, 24 h and 36 h was higher than that of patients in the aminophylline group.
The total clinical efficiency at 12 h, 24 h and 36 h was significantly higher than that of the aminophylline group, and the difference was statistically significant (P<0.05); and the incidence of clinical adverse effects at 12 h, 24 h and 36 h was significantly higher than that of the aminophylline group.
The incidence of clinical adverse reactions at 12 h, 24 h and 36 h was also significantly lower than that of the aminophylline group, and the difference was statistically significant (P<0.01). Aminophylline has been used in the treatment of bronchial asthma for a long time, but its therapeutic window is narrow (only 8-20 μg/mL), its onset of action is long and the incidence of adverse reactions is high, and when its effective blood concentration is higher than 20 μg/mL, it can cause a series of adverse reactions, such as nausea, palpitations and arrhythmia. Doxorubicin is a new type of methylxanthine derivative, which adds a xanthine ring structure to the N-7 position of aminophylline molecular structure. It can reduce the airway hyperresponsiveness and reduce the spasm of the whistle via several pathways. These pathways are: (i) inhibition of various inflammatory factors, reducing the inflammatory response of the whistle. (2) Activation of protein kinase A and C, which reduces intracellular Ca2+ concentration and thus reduces myospasm. Since doxorubicin has no adenosine receptor effect, it avoids the effect on heart and blood vessels, and thus can reduce the occurrence of adverse reactions. In conclusion, the efficacy of doxorubicin in bronchial asthma drug therapy is more significant, which can relieve patients' symptoms and signs more quickly and effectively and promote patients' pulmonary function recovery, and at the same time, the drug has a rapid onset of action, fewer adverse effects and high safety, which is more advantageous than the traditional drug aminophylline for clinical application.